Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 8726046, 10 pages
https://doi.org/10.1155/2018/8726046
Review Article

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials

1Department of Cardiology, Guizhou Provincial People’s Hospital, Guiyang, China
2Department of Endocrinology, Guizhou Provincial People’s Hospital, Guiyang, China

Correspondence should be addressed to Wei Liu; moc.621@89wuil

Received 2 October 2017; Revised 17 December 2017; Accepted 1 January 2018; Published 12 March 2018

Academic Editor: Michael Horowitz

Copyright © 2018 Wei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Nathan, P. A. Cleary, J. Y. Backlund et al., “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, “Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus,” JAMA, vol. 287, no. 19, pp. 2563–2569, 2002. View at Publisher · View at Google Scholar
  3. P. Gaede, P. Vedel, N. Larsen, G. V. Jensen, H. H. Parving, and O. Pedersen, “Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 348, no. 5, pp. 383–393, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. K. Mattila and A. de Boer, “Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus,” Drugs, vol. 70, no. 17, pp. 2229–2245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. E. Cryer, “Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes,” Diabetologia, vol. 45, no. 7, pp. 937–948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Horvath, K. Jeitler, A. Berghold et al., “Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 2, article D5613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. K. J. Lipska, J. S. Ross, Y. Wang et al., “National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011,” JAMA Internal Medicine, vol. 174, no. 7, pp. 1116–1124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Heise, L. Hermanski, L. Nosek, A. Feldman, S. Rasmussen, and H. Haahr, “Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes,” Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 859–864, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Heise, L. Nosek, S. G. Bottcher, H. Hastrup, and H. Haahr, “Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 14, no. 10, pp. 944–950, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Zinman, G. Fulcher, P. V. Rao et al., “Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial,” The Lancet, vol. 377, no. 9769, pp. 924–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. I. Birkeland, P. D. Home, U. Wendisch et al., “Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine,” Diabetes Care, vol. 34, no. 3, pp. 661–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Zinman, A. Philis-Tsimikas, B. Cariou et al., “Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long),” Diabetes Care, vol. 35, no. 12, pp. 2464–2471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Garber, A. B. King, S. Del Prato et al., “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial,” Lancet, vol. 379, no. 9825, pp. 1498–1507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Heller, J. Buse, M. Fisher et al., “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial,” The Lancet, vol. 379, no. 9825, pp. 1489–1497, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Vora, T. Christensen, A. Rana, and S. C. Bain, “Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials,” Diabetes Therapy, vol. 5, no. 2, pp. 435–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Pan, J. L. Gross, W. Yang et al., “A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naive patients with type 2 diabetes mellitus,” Drugs in R&D, vol. 16, no. 2, pp. 239–249, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Warren, L. B. Chaykin, S. Jabbour et al., “Insulin degludec 200 units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 units/mL in patients with type 2 diabetes requiring high-dose insulin,” Clinical Diabetes, vol. 35, no. 2, pp. 90–95, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Wysham, A. Bhargava, L. Chaykin et al., “Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial,” JAMA, vol. 318, no. 1, pp. 45–56, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” Annals of Internal Medicine, vol. 151, no. 4, pp. 264–269, 2009. View at Publisher · View at Google Scholar
  20. Y. Onishi, Y. Iwamoto, S. J. Yoo, P. Clauson, S. C. Tamer, and S. Park, “Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial,” Journal of Diabetes Investigation, vol. 4, no. 6, pp. 605–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. C. Gough, A. Bhargava, R. Jain, H. Mersebach, S. Rasmussen, and R. M. Bergenstal, “Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial,” Diabetes Care, vol. 36, no. 9, pp. 2536–2542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Mathieu, P. Hollander, B. Miranda-Palma et al., “Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 3, pp. 1154–1162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Meneghini, S. L. Atkin, S. C. Gough et al., “The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes,” Diabetes Care, vol. 36, no. 4, pp. 858–864, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. P. Marso, M. G. DK, B. Zinman et al., “Efficacy and safety of degludec versus glargine in type 2 diabetes,” The New England Journal of Medicine, vol. 377, no. 8, pp. 723–732, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Iga, H. Uchino, K. Kanazawa et al., “Glycemic variability in type 1 diabetes compared with degludec and glargine on the morning injection: an open-label randomized controlled trial,” Diabetes Therapy, vol. 8, no. 4, pp. 783–792, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Lane, T. S. Bailey, G. Gerety et al., “Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial,” JAMA, vol. 318, no. 1, pp. 33–44, 2017. View at Publisher · View at Google Scholar · View at Scopus
  27. E. W. Gregg, Y. Li, J. Wang et al., “Changes in diabetes-related complications in the United States, 1990–2010,” The New England Journal of Medicine, vol. 370, no. 16, pp. 1514–1523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Kunt and F. J. Snoek, “Barriers to insulin initiation and intensification and how to overcome them,” International Journal of Clinical Practice. Supplement, vol. 63, no. s164, pp. 6–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Chow, A. Bernjak, S. Williams et al., “Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk,” Diabetes, vol. 63, no. 5, pp. 1738–1747, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Heller, C. Mathieu, R. Kapur, M. L. Wolden, and B. Zinman, “A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia,” Diabetic Medicine, vol. 33, no. 4, pp. 478–487, 2016. View at Publisher · View at Google Scholar · View at Scopus